Inappropriate modulation of the renin angiotensin system (RAS) can lead to derangements of blood pressure homeostasis in humans. Cyp1a1-mRen2.F transgenic rats were used to define the renal mechanisms underlying the development of angiotensin II-dependent hypertension. These transgenic rats were previously generated by introducing the mouse Ren2 gene into the rat genome under the control of a Cyp1a1 inducible promoter. The aim of the current investigation was to establish the contribution of renal function to the development of hypertension in the Cyp1a1- mRen2.F transgenic rat. Expression of the mRen2 transgene was induced by daily gavage of indole 3 carbinol (I3C) at the dose of 100mg/kg. Blood pressure was measured in conscious rats after 1, 3 or 7 days of treatment. The control group received the vegetable oil carrier for 7 days. In addition blood pressure, renal haemodynamics and excretory function were measured under thiobutabarbital anaesthesia. Transgene induction caused a progressive increase in blood pressure in a time dependent manner. Neither glomerular filtration rate nor renal blood flow was affected. This indicates proper function of renal autoregulation during the experimental time course. Tubular sodium reabsorption was significantly increased after the first day of transgene induction and this effect was sustained for the duration of treatment. A pharmacological approach was used to localize the increased reabsorption to a specific region of the nephron and was found to reflect increased activity of the thiazide-sensitive cotransporter (NCC). Chronic administration of thiazide significantly blunted the hypertensive response to transgene induction. Similarly AT1 receptor blockade attenuated the hypertensive phenotype and prevented the transgene-induced stimulation of NCC activity. In contrast, mineralocorticoid receptor blockade did not prevent the development of either hypertension or increased NCC activity. The current study suggests that the development of angiotensin II-dependent hypertension is mediated by increased tubular sodium reabsorption. Increased activity of NCC is a key hypertensive mechanism in this model and results directly from the actions of angiotensin II at the AT1 receptor; indirect aldosterone pathways do not play a major role.

The mas proto-oncogene encodes a seven transmembrane protein (MAS) which is suggested to function as a receptor for angiotensin. It (MAS) was initially identified in NIH-3T3 cells that were transformed with DNA isolated from a human epidermoid carcinoma. These cells formed foci in culture and tumors when injected into nude mice. On the other hand, untransformed cells did not. Further analysis of these cells showed that transformed cells bind increased levels of angiotensin when compared to untransformed cells. These studies also demonstrated that the Mas protein was structurally similar to the angiotensin receptor transmembrane proteins, AT1 and AT2 . This investigation was undertaken to examine the ability of the Mas protein to function as an receptor for angiotensin and promote cell proliferation. To this end, quantitation of mas genes by Polymerase Chain Reaction (PCR) and serial dilutions, and Southern blot analysis support an increased in mas genes in transformed cells. Northern blot analysis demonstrated an increased expression of the mas gene in transformed cells. No changes in the level of the AT2 angiotensin receptor gene expression was observed in the transformed and untransformed cell lines. Expression of the AT1 angiotensin receptor gene was not observed in these cell lines. Anti-peptide antibodies were generated against the 1st and 2nd extracellular regions of the Mas protein. Flow cytometric analysis using these antibodies indicated an increased presence of the Mas protein on the surf ace of transformed cells recognized by anti-peptide antibodies. Western blot analysis showed two cross-reacting proteins of approximately ll0kd and 66kd in transformed cells; whereas, only a 66kd protein was found in untransformed cells. Transformed cells exposed to mas antisense oligos greatly reduced the synthesis of Mas, decreased cell proliferation and the binding of angiotensin. Binding studies using [3H]-DUP- 753 (a non-peptidyl ligand which recognizes Ang subtype AT1 receptors) showed little binding to transformed cells. Similar studies using PD-123319 (a non-peptidyl ligand that recognizes AT2 subtype receptors) indicated that approximately 60% of [125I]-Ang II was displaced using PD-123319. Further binding analysis of transformed cells suggests that [Sarl]-Ang II (an Ang II antagonist) could not completely displace [ 125I]-Ang II. Taken together, these data suggest that Mas protein is an Ang receptor which functions in the regulation of cell proliferation. Mas appears to be a member of a subtype different from AT1 or AT2.

Reactive oxygen species (ROS) are continuously generated in cells and are involved in physiological processes including signal transduction but also their damaging effects on biological molecules have been well described. A number of reports in the literature implicate excessive oxidative stress and/or inadequate antioxidant defense in the pathogenesis of cancer, atherosclerosis, chronic and age related disorders. Several studies have indicated that activation of the renin-angiotensin-aldosterone-system can lead to the formation of ROS. Epidemiological studies have revealed higher renal cell cancer incidences and also higher cancer mortalities in hypertensive individuals. Recently, our group has shown that perfusion of the isolated mouse kidney with Ang II or treatment of several cell lines with Ang II leads to formation of DNA damage and oxidative base modifications. Here, we tried to scrutinize the pathway involved in genotoxicity of Ang II. We confirmed the genotoxicity of Ang II in two kidney cell lines of human origin. Ang II treatment led to the production of superoxide anions which we could hinder when we used the membrane permeable superoxide dismutase (SOD) mimetic TEMPOL. One of the enzymes which is activated in the cells after Ang II treatment and is able to produce ROS is NADPH oxidase. We demonstrated the activation of NADPH oxidase in response to Ang II by upregulation of its p47 subunit using RT-PCR. Also, pPhosphorylation of p47 subunit of NADPH oxidase after Ang II treatment was enhanced. Using two inhibitors we showed that NADPH oxidase inhibition completely prevents DNA damage by Ang II treatment. To differentiate between Nox2 and Nox4 isoforms of NADPH oxidase subunits in the genotoxicity of Ang II, we performed siRNA inhibition and found a role only for Nox4, while Nox2 was not involved. Next, we investigated PKC as a potential activator of NADPH oxidase. We showed that PKC becomes phosphorylated after Ang II treatment and also that inhibition of PKC hinders Ang II from damaging the cells. Our results from using several inhibitors of different parts of the pathway revealed that PKC activation in this pathway is dependent on the action of PLC on membrane phospholipids and production of IP3. IP3 binds to its receptor at endoplasmic reticulum (ER), opening a channel which allows calcium efflux into the cytoplasm. In this manner, both ER calcium stores and extracellular calcium cooperate so that Ang II can exert its genotoxic effect. PLC is activated by AT1R stimulation. We could also show that the genotoxicity of Ang II is mediated via AT1R signaling using the AT1R antagonist candesartan. In conclusion, here we have shown that Ang II is able to damage genomic damage in cell lines of kidney origin. The observed damage is associated with production of ROS. A decrease in Ang II-induced DNA damage was observed after inhibition of G-proteins, PLC, PKC and NADPH oxidase and interfering with intra- as well as extracellular calcium signaling. This leads to the following preliminary model of signaling in Ang II-induced DNA damage: binding of Ang II to the AT1 receptor activates PLC via stimulation of G-proteins, resulting in the activation of PKC in a calcium dependent manner which in turn, activates NADPH oxidase. NADPH oxidase with involvement of its Nox4 subunit then produces reactive oxygen species which cause DNA damage. Dopamine content and metabolism in the peripheral lymphocytes of PD patients are influenced by L-Dopa administration. The PD patients receiving a high dose of L-Dopa show a significantly higher content of dopamine in their lymphocytes compared to PD patients who received a low dose of L-Dopa or the healthy control. Central to many of the processes involved in oxidative stress and oxidative damage in PD are the actions of monoamine oxidase (MAO), the enzyme which is responsible for the enzymatic oxidation of dopamine which leadsing to production of H2O2 as a by-product. We investigated whether dopamine oxidation can cause genotoxicity in lymphocytes of PD patents who were under high dose L-Dopa therapy and afterward questioned the occurrence of DNA damage after dopamine treatment in vitro and tried to reveal the mechanism by which dopamine exerts its genotoxic effect. The frequency of micronuclei in peripheral blood lymphocytes of the PD patients was not elevated compared to healthy age-matched individuals, although the formation of micronuclei revealed a positive correlation with the daily dose of L-Dopa administration in patients who received L-Dopa therapy together with dopamine receptor agonists. In vitro, we describe an induction of genomic damage detected as micronucleus formation by low micromolar concentrations in cell lines with of different tissue origins. The genotoxic effect of dopamine was reduced by addition of the antioxidants TEMPOL and dimethylthiourea which proved the involvement of ROS production in dopamine-induced DNA damage. To determine whether oxidation of dopamine by MAO is relevant in its genotoxicity, we inhibited MAO with two inhibitors, trans-2-phenylcyclopropylamine hydrochloride (PCPA) and Ro 16-6491 which both reduced the formation of micronuclei in PC-12 cells. We also studied the role of the dopamine transporter (DAT) and dopamine type 2 receptor (D2R) signaling in the genotoxicity of dopamine. Inhibitors of the DAT, GBR-12909 and nomifensine, hindered dopamine-induced genotoxicity. These results were confirmed by treatment of MDCK and MDCK-DAT cells, the latter containing the human DAT gene, with dopamine. Only MDCK-DAT cells showed elevated chromosomal damage and dopamine uptake. Although stimulation of D2R with quinpirole in the absence of dopamine did not induce genotoxicity in PC-12 cells, interference with D2R signaling using D2R antagonist and inhibition of G-proteins, phosphoinositide 3 kinase and extracellular signal-regulated kinases reduced dopamine-induced genotoxicity and affected the ability of DAT to take up dopamine. Furthermore, the D2R antagonist sulpiride inhibited the dopamine-induced migration of DAT from cytosol to cell membrane. Overall, the neurotransmitter dopamine causes DNA damage and oxidative stress in vitro. There are also indications that high dose L-Dopa therapy might lead to oxidative stress. Dopamine exerts its genotoxicity in vitro upon transport into the cells and oxidization oxidation by MAO. Transport of dopamine by DAT has the central role in this process. D2R signaling is involved in the genotoxicity of dopamine by affecting activation and cell surface expression of DAT and hence modulating dopamine uptake. We provided evidences for receptor-mediated genotoxicity of two compounds with different mechanism of actions. The involvement of these receptors in many human complications urges more investigations to reveal whether abnormalities in the endogenous compounds-mediated signaling can play a role in the initiation of new conditions like carcinogenesis. / Reaktive Sauerstoffspezies (ROS) werden kontinuierlich in Zellen generiert und sind an physiologischen Prozessen wie der Signaltransduktion beteiligt. Aber auch ihre schädigenden Auswirkungen auf biologische Moleküle sind seit langem bekannt. Eine Reihe von Literaturberichten sieht einen Zusammenhang zwischen übermäßigem oxidativen Stress oder einer unzureichenden antioxidativen Verteidigung und Krebs, Atherosklerose und chronischen bzw. altersbedingten Erkrankungen. Mehrere Studien haben belegt, dass die Aktivierung des Renin-Angiotensin-Aldosteron-Systems zur Bildung von ROS führen kann. Epidemiologische Studien haben gezeigt, dass Nierenkarzinom-Inzidenzen und -Mortalitäten bei Hypertonikern erhöht sind. Vor kurzem konnte unsere Gruppe zeigen, dass die Perfusion von isolierten Maäusen-Nieren und dieoder Behandlung mehrerer Zelllinien mit Angiotensin II (Ang II) zur Bildung von DNA-Schäden und oxidativen Basenmodifikationen führt. Ziel der vorliegenden Arbeit war es, die Signalwege der Genotoxizität von Ang II zu bestimmen. Wir bestätigten dDie Genotoxiziät von Ang II in zwei Nieren-Zelllinien humaner Herkunft konnte bestätigt werden. Wir zeigten, dass Ang II-Behandlung zur Produktion von Superoxid-Anionen führt, die durch das membrangängige Superoxid-Dismutase-Mimetikum TEMPOL verhindert werden kann. Eines der Enzyme, das in den Zellen nach Ang II-Behandlung aktiviert wird und ROS produzieren kann, ist die NADPH-Oxidase. Die mittels RT-PCR gemessene Hochregulierung von p47 beweist die Aktivierung der NADPH-Oxidase nach Ang II-Behandlung. Auch die Phosphorylierung von p47 nach Ang II-Behandlung wurde gesteigert. Mittels zweier Inhibitoren zeigten wir, dass NADPH-Oxidase-Hemmung DNA-Schäden durch Ang II-Behandlung vollständig verhindert. Wir versuchten, die Rolle der Nox2- und Nox4-Isoformen der NADPH-Oxidase-Untereinheiten bei der Genotoxizität von Ang II zu differenzieren. Hemmung mittels siRNA bestätigte nur eine Beteiligung der Nox4. Anschließend überprüften wir die Rolle der PKC als potentiellem Aktivator der NADPH-Oxidase. Wir zeigten, dass die PKC nach Ang II-Behandlung PKC phosphoryliert wird und durch die Hemmung der PKC Ang II-induzierten Schäden verhindert werdenird. Die Verwendung mehrerer Inhibitoren der verschiedenen Teile des Signalweges zeigte, dass die PKC-Aktivierung von der Reaktion der PLC mit Membranphospholipiden und der Produktion von IP3 und DAG abhängig ist. IP3 bindet an seinen Rezeptor am Endoplasmatischen Retikulum (ER)., dDie in der Folge auftretende Öffnung eines Kanals ermöglicht einen Calcium-Ausstrom in das Cytoplasma. Auf diese Weise sind sowohl ER-Calcium als auch extrazelluläres Calcium an der Ang II-induzierten genotoxische Wirkung beteiligt. PLC wird durch AT1R-Stimulation aktiviert. Wir konnten mit Hilfe des AT1R-Antagonisten Candesartan auch zeigen, dass die Genotoxizität von Ang II über AT1R-Signaltransduktion vermittelt wird. Zusammenfassend haben wir gezeigt, dass Ang II genomische Schäden in humanen Nieren-Zelllinien verursacht. Die Schäden sind mit der Produktion von ROS verbunden. Eine Reduktion der Ang II-induzierten DNA-Schäden wurde nach Hemmung vonder G-Proteinen, der PLC, PKC und NADPH-Oxidase und Beeinflussung intra- sowie extrazellulärer Calium-Signalgebung gezeigt. Dies führt zu folgendem vorläufigen Modell der Signaltransduktion der von Ang II-induzierten DNA-Schäden: Die Bindung von Ang II an den AT1-Rezeptor aktiviert die PLC durch Stimulationerung der G-Proteine und die PKC in Calcium-abhängiger Weise, dies wiederum aktiviert die NADPH-Oxidase. Die NADPH Oxidase unter Beteiligung ihrerseiner Nox4-Untereinheit erzeugt dann reaktive Sauerstoffspezies, die DNA-Schäden verursachen. Dopamingehalt und -stoffwechsel in peripheren Lymphozyten von Parkinson-Patienten werden durch L-Dopa-Gabe beeinflusst. Die Patienten, die eine hohe Dosis L-Dopa erhalten, zeigen einen signifikant höheren Gehalt an Dopamin in den Lymphozyten im Vergleich zu Patienten, die eine niedrige Dosis L-Dopa erhalten oder der gesunden Kontrollgruppe. Im Mittelpunkt vieler Prozesse bei der Entstehung von oxidativem Stress und oxidativer Schäden bei Parkinson-Patienten steht die Monoaminoxidase (MAO), die für die enzymatische Oxidation von Dopamin und in der Folge für die Entstehung von H2O2 verantwortlich ist. Wir untersuchten, ob die Oxidation von Dopamin genotoxische Wirkung in Lymphozyten von Parkinson-Patienten mit hochdosierter L-Dopa-Therapie induzieren kann. Danach überprüftenfragten wir, ob die Behandlung mit Dopamin in vitro DNA-Schäden induzieren kann und versuchten aufzuzeigen, durch welchen Mechanismus Dopamin seine genotoxische Wirkung entfaltet. Die Häufigkeit von Mikrokernen in peripheren Lymphozyten der Parkinson-Patienten war nicht erhöht im Vergleich zur gesunden Kontrollgruppe, allerdings zeigte die Mikrokernfrequenz eine positive Korrelation mit der täglichen L-Dopa-Dosis bei Patienten, die eine L-Dopa-Therapie zusammen mit einem Dopamin-Rezeptor-Agonisten erhielten. In vitro beobachteten wir bei niedrigen mikromolaren Konzentrationen eine Induktion des genomischen Schadens in Zelllinien, die aus verschiedenen Geweben stammten. Die genotoxische Wirkung von Dopamin wurde durch Zugabe der Antioxidantien TEMPOL und DMTU reduziert, wodurch die Beteiligung von ROS gezeigt werden konnte. Um festzustellen, ob die Oxidation von Dopamin durch MAO für die Genotoxizität relevant ist, hemmten wir MAO mit zwei Inhibitoren, trans-2-Phenylcyclopropylamin-Hydrochlorid (PCPA) und Ro 16-6491, die beide die Bildung von Mikrokernen in PC-12-Zellen reduzieren konnten. Wir untersuchten auch die Rolle des Dopamin-Transporters (DAT) und Dopamin-Typ-2-Rezeptor (D2R)-assoziierter Signalwege in der Genotoxizität von Dopamin. Die Inhibitoren des DAT, GBR-12909 und Nomifensin verhinderten die Dopamin-induzierte Genotoxizität. Diese Ergebnisse wurden durch Behandlung von MDCK- und MDCK-DAT- Zellen (die das humane DAT-Gen besitzen) mit Dopamin bestätigt. Nur MDCK-DAT-Zellen zeigten erhöhte chromosomale Schäden und Dopaminaufnahme. Obwohl die Stimulation mit dem D2R-Rezeptor-Agonisten Quinpirol in Abwesenheit von Dopamin keine Genotoxizität in PC-12-Zellen induzierte, reduzierten sowohl ein D2R-Antagonist, wie auch Inhibitoren des in der Signalkaskade involvierten G-Proteins, der Phosphoinositol-3-Kinase und der extrazellulären signalregulierten Kinasen die Aufnahme von Dopamin mittels DAT und die Dopamin-vermittelte Genotoxizität. Der D2R-Antagonist Sulpirid hemmte die Dopamin-induzierte Migration von DAT aus dem Cytosol zur Zellmembran. Insgesamt verursacht der Neurotransmitter Dopamin DNA-Schäden und oxidativen Stress in vitro. Es gibt Hinweise, dass eine hochdosierte L-Dopa-Therapie zu oxidativem Stress führt. In vitro führt Dopamin zu Genotoxizität durch den Transport in die Zellen und Oxidation durch MAO. Der Transport von Dopamin durch DAT spielt eine zentrale Rolle in diesem Prozess. Die D2R-Signalwege sind an der Genotoxizität von Dopamin durch Auswirkung auf die Aktivierung und Membranexpression von DAT und damit der Dopaminaufnahme beteiligt.

by Chi-shing Sum. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1995. / Includes bibliographical references (leaves 84-96). / ACKNOWLEDGEMENT --- p.i / ABSTRACT --- p.ii / LIST OF ABBREVIATIONS --- p.iv / TABLE OF CONTENTS --- p.v / Chapter CHAPTER 1 --- p.1 / Chapter 1.1 --- Biochemistry of Renin-Angiotensin System --- p.1 / Chapter 1.2 --- Physiological Roles of Angiotensin --- p.5 / Chapter 1.3 --- Biochemistry of Angiotensin Receptors --- p.6 / Chapter 1.4 --- Tissue Renin-Angiotensin System --- p.13 / Kidney --- p.13 / Blood vessels --- p.14 / Heart --- p.15 / Brain --- p.16 / Testes --- p.17 / Chapter 1.5 --- Structure and Function of Vas Deferens --- p.18 / Chapter 1.6 --- Aim of Study --- p.21 / Chapter CHAPTER 2 --- p.22 / Chapter 2.1 --- introduction --- p.22 / Chapter 2.2 --- Materials --- p.23 / Chapter 2.3 --- methods --- p.23 / Chapter 2.3.1 --- Preparation of isolated epididymal rat vas deferens --- p.23 / Chapter 2.3.2 --- Concentration-responses to angiotensins --- p.24 / Chapter 2.3.3 --- Effects of angiotensin II in the presence of protease inhibitors --- p.24 / Chapter 2.3.4 --- Effect of losartan and CGP 42112 --- p.24 / Chapter 2.3.5 --- Schild analysis --- p.25 / Chapter 2.3.6 --- Interaction of angiotensin II with exogenous noradrenaline --- p.25 / Chapter 2.3.7 --- Statistical analysis --- p.25 / Chapter 2.4 --- results --- p.25 / Chapter 2.4.1 --- Effect of angiotensin on epididymal rat vas deferens --- p.25 / Chapter 2.4.2 --- Concentration-responses to angiotensins in epididymal rat vas deferens --- p.27 / Chapter 2.4.3 --- Effect of angiotensin II in the presence of protease inhibitors --- p.27 / Chapter 2.4.4 --- Effect of losartan ami CGP 42112 --- p.27 / Chapter 2.4.5 --- Schild analysis --- p.36 / Chapter 2.4.6 --- Interaction of angiotensin II with exogenous noradrenaline --- p.36 / Chapter 2.5 --- Discussion --- p.36 / Chapter CHAPTER 3 --- p.39 / Chapter 3.1 --- Introduction --- p.39 / Chapter 3.2 --- Materials --- p.39 / Chapter 3.3 --- Methods --- p.40 / Chapter 3.3.1 --- Preparation of isolated prostatic rat vas deferens --- p.40 / Chapter 3.3.2 --- Concentration-responses to angiotensins --- p.40 / Chapter 3.3.3 --- Effects of angiotensin II in the presence of protease inhibitors --- p.41 / Chapter 3.3.4 --- Effect oflosartan and CGP 42112 --- p.41 / Chapter 3.3.5 --- Schild analysis --- p.41 / Chapter 3.3.6 --- Interaction of angiotensin II with exogenous noradrenaline --- p.42 / Chapter 3.3.7 --- Concentration-response to angiotensin II after reserpine treatment --- p.42 / Chapter 3.3.8 --- Concentration-response to angiotensin II after desensitization of P2-purinoceptors --- p.42 / Chapter 3.3.9 --- Statistical analysis --- p.42 / Chapter 3.4 --- Results --- p.43 / Chapter 3.4.1 --- Effect of angiotensin on prostatic rat vas deferens --- p.43 / Chapter 3.4.2 --- Concentration-responses to angiotensins in prostatic rat vas deferens --- p.43 / Chapter 3.4.3 --- Effect of angiotensin II in the presence of protease inhibitors --- p.43 / Chapter 3.4.4 --- Effect of losartan and CGP 42112 --- p.49 / Chapter 3.4.5 --- Schild analysis --- p.49 / Chapter 3.4.6 --- Interaction of angiotensin II with exogenous noradrenaline --- p.49 / Chapter 3.4.7 --- Concentration-response to angiotensin II afier reserpine treatment --- p.54 / Chapter 3.4.8 --- Concentration-response to angiotensin II after desensitization of P2-purinoceptors --- p.54 / Chapter 3.5 --- Discussion --- p.63 / Chapter CHAPTER 4 --- p.66 / Chapter 4.1 --- introduction --- p.66 / Chapter 4.2 --- Materials and Methods --- p.66 / Chapter 4.2.1 --- Preparation of polyclonal angiotensin II antiserum --- p.66 / Chapter 4.2.1.1 --- Preparation of peptide conjugate --- p.66 / Chapter 4.2.1.2 --- Protein determination --- p.67 / Chapter 4.2.1.3 --- Immunization of rabbit with peptide conjugate --- p.67 / Chapter 4.2.1.4 --- Collecting rabbit serum --- p.68 / Chapter 4.2.2 --- Characterization of BSA-Ang II and Thy-Ang II antisera --- p.68 / Chapter 4.2.2.1 --- Slot blotting --- p.68 / Chapter 4.2.2.2 --- Enzyme-linked immunosorbent assay (ELISA) --- p.69 / Chapter 4.3 --- RESULT --- p.69 / Chapter 4.3.1 --- Preparation of polyclonal angiotensin II antiserum --- p.69 / Chapter 4.3.2 --- Characterization of BSA-Ang II and Thy-Ang II antisera --- p.70 / Chapter 4.3.2.1 --- Slot blotting --- p.70 / Chapter 4.3.2.2 --- Enzyme-linked immunosorbent assay (ELISA) --- p.70 / Chapter 4.3 --- discussion --- p.76 / Chapter CHAPTER 5 --- p.78 / Chapter 5. 1 --- General Discussions --- p.78 / REFERENCES --- p.84 / APPENDIX --- p.97 / Published Abstract and Paper --- p.97

Wei, Lihua. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 166-196). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 109-124).

Aging is associated with increases in regional and systemic vascular resistance and impaired ability to increase blood flow to active muscles during exercise. Aging enhances vasoconstrictor responsiveness in both humans and animals, and an increase in Angiotensin II-induced vasoconstriction is one possible mechanism for old age-associated increase in muscle vascular resistance. The purpose of this study was to determine 1) whether aging alters Ang II-induced vasoconstriction, 2) whether exercise training attenuates the age-associated alteration in Ang II-mediated vasoconstriction, and 3) the mechanism(s) through which aging and exercise training alter Ang II-induced vasoconstriction in rat skeletal muscle arterioles. Male Fischer 344 rats were assigned to 4 groups: Young sedentary (YS; 4 months), old sedentary (OS; 24 months), young trained (YT) and old trained (OT). Exercise-trained groups performed treadmill exercises for 60 min/day at 15 m/min, on a 15º incline for 5 days/week for 10-12 weeks. First-order (1A) arterioles were isolated from soleus and gastrocnemius muscles for in vitro experimentation. Intraluminal diameter changes were determined in response to the cumulative addition of Ang II (3×10-11 - 3×10-5 M). Ang II dose responses were then determined following the removal of endothelium and treatment with NG-nitro-L-arginine methyl ester (L-NAME, 10-5 M), a nitric oxide synthase (NOS) inhibitor. Ang II-induced vasoconstriction was augmented in the aged skeletal muscle arterioles, both in soleus and gastrocnemius muscles, and age-associated increases in Ang II-induced vasoconstriction were abolished with the removal of endothelium and with L-NAME. Exercise training ameliorated the age-induced increase in Ang II-vasoconstriction, and this alteration was eliminated by the removal of endothelium and with NOS inhibition. These findings suggest that aging enhances Ang II-induced vasoconstrictor responses in the arterioles from both soleus, high oxidative, and white portion of gastrocnemius, low oxidative glycolytic muscles, and this age-associated change occurs through an endothelium-dependent NOS signaling pathway. These results also demonstrated that exercise training can ameliorate the age-associated increase in Ang II vasoconstriction in the arterioles from both high oxidative and low oxidative glycolytic muscles through an endothelium-mediated NOS mechanism.

The renin-angiotensin system (RAS) is critical for the control of blood pressure (BP) and salt balance in mammals. Studies reveal that local RAS are present in the rat brain and renin is the first effector of the brain RAS for generating angiotensin II (Ang II) which exerts diverse physiological actions in both peripheral and central nervous system. The existence of renin within the brain has now been demonstrated by numerous studies. Previous studies suggest that renin may go through angiotensin-dependent and independent pathway to influence vascular tone, by Ang II type 1 receptor (AT1R) and renin specific (pro)renin receptor (PRR), respectively. Studies also indicate that AT1R and PRR are highly expressed in the nucleus tractus solitarii (NTS), which is important for central feedback regulation of BP. Further studies have shown that Ang II contributes to the release of NO, which plays an important role in cardiovascular regulation in the NTS. These results indicate that renin plays cardiovascular modulatory role in the NTS. However, the mechanisms how renin modulate cardiovascular functions in the NTS remained unclear. In the present study, I investigated the molecular mechanisms of renin-induced cardiovascular effects in the NTS. Unilateral microinjection of renin into the NTS of WKY rats produced prominent depressor and bradycardic effects. Pretreatment with a non-selective NOS inhibitor L-NAME, eNOS specific inhibitor L-NIO, Akt inhibitor IV, and PI3K inhibitor LY294002 significantly attenuated the cardiovascular response evoked by renin, whereas nNOS specific inhibitor Vinyl-L-NIO and MEK inhibitor PD98059 did not cause significant changes. Western blot studies showed renin increased eNOSS1177 and AktS473 phosphorylation instead of nNOSS1416 and ERK1/2T202/Y204 phosphorylation, and pretreatment with LY294002 blocked renin-induced eNOSS1177 and AktS473 phosphorylation. These results indicated that renin might go through PI3K-Akt-eNOS pathway to increase eNOS activity and ultimately result in NO release. The cardiovascular effects of renin were also attenuated by renin specific inhibitor aliskiren, angiotensin converting enzyme inhibitor lisinopril, AT1R antagonist losartan, and intracellular Ca2+ chelator, BAPTA-AM instead of G protein £]£^ subunit inhibitor gallein, PLC inhibitor U73122, calmodulin inhibitor (W-7) and (pro)renin receptor blocker, handle region peptide. These results indicated that renin mainly through AT1R to regulate BP. Therefore, my results indicated that the modulation of cardiovascular effects of renin in the NTS involves AT1R-PI3K-Akt pathway to activate eNOS activation.

Aging is associated with increases in regional and systemic vascular resistance and impaired ability to increase blood flow to active muscles during exercise. Aging enhances vasoconstrictor responsiveness in both humans and animals, and an increase in Angiotensin II-induced vasoconstriction is one possible mechanism for old age-associated increase in muscle vascular resistance. The purpose of this study was to determine 1) whether aging alters Ang II-induced vasoconstriction, 2) whether exercise training attenuates the age-associated alteration in Ang II-mediated vasoconstriction, and 3) the mechanism(s) through which aging and exercise training alter Ang II-induced vasoconstriction in rat skeletal muscle arterioles. Male Fischer 344 rats were assigned to 4 groups: Young sedentary (YS; 4 months), old sedentary (OS; 24 months), young trained (YT) and old trained (OT). Exercise-trained groups performed treadmill exercises for 60 min/day at 15 m/min, on a 15º incline for 5 days/week for 10-12 weeks. First-order (1A) arterioles were isolated from soleus and gastrocnemius muscles for in vitro experimentation. Intraluminal diameter changes were determined in response to the cumulative addition of Ang II (3×10-11 - 3×10-5 M). Ang II dose responses were then determined following the removal of endothelium and treatment with NG-nitro-L-arginine methyl ester (L-NAME, 10-5 M), a nitric oxide synthase (NOS) inhibitor. Ang II-induced vasoconstriction was augmented in the aged skeletal muscle arterioles, both in soleus and gastrocnemius muscles, and age-associated increases in Ang II-induced vasoconstriction were abolished with the removal of endothelium and with L-NAME. Exercise training ameliorated the age-induced increase in Ang II-vasoconstriction, and this alteration was eliminated by the removal of endothelium and with NOS inhibition. These findings suggest that aging enhances Ang II-induced vasoconstrictor responses in the arterioles from both soleus, high oxidative, and white portion of gastrocnemius, low oxidative glycolytic muscles, and this age-associated change occurs through an endothelium-dependent NOS signaling pathway. These results also demonstrated that exercise training can ameliorate the age-associated increase in Ang II vasoconstriction in the arterioles from both high oxidative and low oxidative glycolytic muscles through an endothelium-mediated NOS mechanism.

The rostral ventrolateral medulla (RVLM) is the origin of a ¡§life-and-death¡¨ signal identifies from systemic arterial blood pressure spectrum that reflects failure of central cardiovascular regulation during brain stem death. It is also a target site where endogenous angiotensin II acts on angiotensin II type 1 receptors (AT1R) to increase blood pressure (BP); or on type 2 receptors (AT2R) to inhibit baroreceptor reflex (BRR) response. This study investigated the roles of AT1R and AT2R and their signaling pathways in RVLM for ¡§life-and-death¡¨ signal response during experimental brain stem death, using organophosphate mevinphos (Mev) as the experimental insult. In Sprague-Dawley rats, Mev (640 £gg/kg, i.v.) elicited an increase (pro-life phase) followed by a decrease (pro-death phase). Real-time PCR analysis revealed that whereas AT1R level underwent a 10% increase at pro-life phase, AT2R exhibited a significance increase of up to 40% at pro-death phase. Western blot analysis revealed that whereas AT1R level underwent a 20% increase at pro-life phase, AT2R exhibited a significant increase of up to 50% at pro-death phase. Pretreatment with microinjection of an AT1R antagonist losartan (2 nmol) into RVLM elicited abrupt death because of drastic hypotension through inhibiting NADPH oxidase and its downstream superoxide anion. Pretreatment with NADPH oxidase inhibitor DPI (1.5 nmol) inhibited NADPH oxidase avtiviting and superoxide anion production and decreased ¡§life-and-death¡¨ signal at pro-life phase; using superoxide anion inhibitor tempol (5 nmol) potentiated blood pressure and ¡§life-and-death¡¨ signal at pro-death phase. However, pretreatment with an AT2R antagonist PD123319 (2 nmol) potentiated the ¡§life-and-death¡¨ signal and antagonized hypotension during pro-death phase through inhibiting protein phosphotase 2A (PP2A) then activating extracellular signal-regulated kinase 1/2 (ERK1/2). Similar to AT2R antagonist PD123319, pretreatment with PP2A inhibitor okadaic acid (0.5 fmol) inhibit PP2A, leading to activation of ERK1/2, potentiate ¡§life-and-death¡¨ signal and antagonized hypotension during pro-death phase. These results suggest that AT1R in RVLM plays a ¡§pro-life¡¨ role through NADPH oxidase/superoxide anion during experimental brain stem death by maintaining BP and ¡§life-and-death¡¨ signal; AT2R plays a ¡§pro-death¡¨ role through PP2A/ERK1/2 by inhibiting BP and ¡§life-and-death¡¨ signal, and superoxide may also plays a ¡§pro-life and pro-death¡¨ role at pro-death phase.